Burzynski Research Institute Inc (BZYR) Return on Equity ROE from the third quarter 2026 to third quarter 2025 and annually, average high and low, overall ranking from Nov 30 2025 to Nov 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Burzynski Research Institute Inc  (NONE: BZYR)

Burzynski Research Institute Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Burzynski Research Institute Inc in the third quarter 2026?
Due to the lack of equity, it was not possible to calculate Burzynski Research Institute Inc's return on equity (ROE) in its third quarter 2026

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Nov 30 2025)
III. Quarter		 (Aug 31 2025)
II. Quarter		 (May 31 2025)
I. Quarter		 (Feb 28 2025)
IV. Quarter		 (Nov 30 2024)
III. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -1 -1 -1 -1 -1
Return On Equity (TTM) - - - - -
BZYR's Total Ranking # # # # #
Equity (TTM) in Millions 0 0 0 0 0
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to BZYR Management Effectiveness >> BZYR's 5 Years Annual ROE >> Compare BZYR ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





BZYR Annual Return On Equity (Feb 28 2025)
2025		 (Feb 29 2024)
2024		 (Feb 28 2023)
2023		 (Feb 28 2022)
2022		 (Feb 28 2021)
2021
Total Equity in Millions 0 0 0 0 0
Y / Y Equity Change - - - - -
Net Income in Millions -1 -1 -1 -1 -1
Y / Y Net Income Change - - - - -
Return On Equity - - - -80983.08 % -

Back to BZYR Management Effectiveness >> BZYR's 5 Years Annual ROE >> Compare BZYR ROE to its Competitors




More Return On Equity Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
BZYR's' Return on Equity at Yahoo Finance
BZYR's Roe Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for BZYR's Competitors
Subscribers only: Roe for Burzynski Research Institute Inc's Suppliers
Subscribers only: Return On Equity for BZYR's Customers




Companies with similar Return On Equity at Nov 30 2025, within Healthcare Sector ROE
Q32 Bio Inc   1,630.23 %
Aveanna Healthcare Holdings Inc   983.51 %
Petros Pharmaceuticals inc   858.01 %
Coherus Oncology inc   789.35 %
Omada Health Inc   630.34 %
Interpace Biosciences Inc   484.95 %

Date modified: 2026-01-19T15:02:34+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.